Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November
November 10, 2026
The Enzutrix patent dispute is set to be heard by South Africa’s Constitutional Court on Monday, 23 November 2026. The University of California (UC) and Astellas Pharma Inc. accuse Eurolab (Pty) Ltd and the Dis-Chem companies of infringing South African patent 2007/10870, which covers enzalutamide, the active ingredient in Xtandi. Eurolab sells the generic as Enzutrix, also spelled Enzutix in some reports. UC is pursuing a multimillion-rand damages claim, and Eurolab argues that UC was never entitled to the patent.
How the case reached the top court
Eurolab obtained registration for Enzutrix from the South African Health Products Regulatory Authority (SAHPRA) in January 2023. UC and Astellas asked the company to undertake not to launch for the life of the patent. Eurolab refused and went to the Commissioner of Patents, arguing that UC had not been entitled to apply for the patent.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.